Corline Biomedical AB (CLBIO.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 14.50 (+6.62%) as of
Key statistics
- Market cap
- 378.93M
- Forward P/E
- 16.29
- EPS (TTM)
- -0.49
- Dividend yield
- 0.00%
- 52-week range
- 13.05 – 20.50
- Beta
- 0.34
- Revenue (TTM)
- 12.39M
- Profit margin
- -99.47%
- Analyst target
- SEK 24.50
- Volume
- 27.67k
About Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. It offers CHS stent, a metallic tube-shaped device for the treatment of acute or threatened vessel closure during coronary angioplasty; CHS Coated Ablation Catheter to treat heart arrythmia; Renaparin for use in the treatment of end stage renal failure; and CHC, which is used for the treatment of soft tissue injuries. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Uppsala, Sweden
- Employees
- 14
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.